<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03079310</url>
  </required_header>
  <id_info>
    <org_study_id>107451</org_study_id>
    <nct_id>NCT03079310</nct_id>
  </id_info>
  <brief_title>Spinal Cord Stimulation for Gait in Parkinson Disease</brief_title>
  <official_title>Thoracic Dorsal Spinal Cord Stimulation for the Treatment of Gait and Balance Impairments in Parkinson Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Western University, Canada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Western University, Canada</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Balance and gait impairment increases the risk of falls and contributes to a reduced quality
      of life and shorter survival in Parkinson disease (PD) patients. In preliminary case studies,
      electrical epidural spinal cord stimulation (SCS) has been shown to significantly improve
      gait, postural instability, rigidity, and tremor. Controlled studies for optimizing which
      stimulation settings produce the best clinical response for mobility and gait, and achieving
      these results chronically are all significant unmet needs. Using quantitative laboratory and
      mobile technologies to test a range of stimulation settings, this research study aims to
      determine which SCS parameters or combination of parameters is best suited to effectively
      alleviate disabling symptoms experienced by each PD patient.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective gait analysis</measure>
    <time_frame>12 months</time_frame>
    <description>Spatiotemporal gait parameters will be analyzed for each SCS setting</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in UPDRS-III scores</measure>
    <time_frame>12 months</time_frame>
    <description>UPDRS-III assessment will be assessed pre-surgery and post-surgery at weeks 2, 4, 6, 8, 12, 16, 20, 24, 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in FOG-Q scores</measure>
    <time_frame>12 months</time_frame>
    <description>FOG-Q scores will be assessed pre-surgery and post-surgery at weeks 2, 4, 6, 8, 12, 16, 20, 24, 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in PDQ-8 scores</measure>
    <time_frame>12 months</time_frame>
    <description>PDQ-8 scores will be assessed pre-surgery and post-surgery at weeks 2, 4, 6, 8, 12, 16, 20, 24, 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in ABC scores</measure>
    <time_frame>12 months</time_frame>
    <description>ABC scores will be assessed pre-surgery and post-surgery at weeks 2, 4, 6, 8, 12, 16, 20, 24, 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in QoL scores</measure>
    <time_frame>12 months</time_frame>
    <description>QoL scores will be assessed pre-surgery and post-surgery at weeks 2, 4, 6, 8, 12, 16, 20, 24, 52</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Spinal cord stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Boston Scientific SCS system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Spinal cord stimulation</intervention_name>
    <description>Range of pulse widths (200-500 microseconds) and frequencies (30-130 Hz) will be assessed for each patient</description>
    <arm_group_label>Spinal cord stimulation</arm_group_label>
    <other_name>Boston Scientific Precision® System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consenting male and female participants, aged 18 years to 80 years

          -  Idiopathic PD with II-IV Hoehn-Yahn stage

          -  A history of frequent falls, gait and balance dysfunction and postural instability

          -  Ability to perform a gait/walking task (under close supervision),

          -  PD participants referred by Dr. Jog to the functional neurosurgeon for SCS
             implantation for treatment of their gait and balance dysfunction and/or for their
             freezing of gait.

          -  SCS eligibility has been confirmed by neurologist and neurosurgeon

          -  Patients who receive SCS for their gait and mobility must participate in this study in
             order to determine which SCS parameters provide the patient with the best outcome for
             their PD symptoms.

          -  Montreal Cognitive Assessment (MoCA) score ≥ 26 • able to give informed consent

          -  Able to attend all clinic visits and assessments

          -  No dementia or psychiatric abnormalities on neuropsychological testing

          -  No significant secondary causes (such as cerebrovascular disease, normal pressure
             hydrocephalus, peripheral neuropathy, severe degenerative lower limb or back disease).

        Exclusion Criteria:

          -  History of stroke

               -  History of ALS or Myasthenia Gravis

               -  Offending medications (Lithium, valproate, steroids, amiodarone, beta-adrenergic
                  agonists (e.g. salbutamol).

               -  Persons prescribed zonisamide

               -  Women reporting that they are pregnant

               -  Persons medically unstable with contraindications to SCS will be excluded

               -  Previous brain surgery or cardiac pacemaker

               -  Eligibility for deep brain stimulation surgery

               -  Moderately severe parkinsonism in the context of unstable pharmacological
                  treatment

               -  Dementia as assessed by DSM criteria or severe cognitive disturbances

               -  Severe psychiatric symptoms (in particular, hallucinations and depression)

               -  Bad general health

               -  Lack of compliance at follow-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Fuentes R, Petersson P, Nicolelis MA. Restoration of locomotive function in Parkinson's disease by spinal cord stimulation: mechanistic approach. Eur J Neurosci. 2010 Oct;32(7):1100-8. doi: 10.1111/j.1460-9568.2010.07417.x. Review.</citation>
    <PMID>21039949</PMID>
  </reference>
  <reference>
    <citation>Santana MB, Halje P, Simplício H, Richter U, Freire MAM, Petersson P, Fuentes R, Nicolelis MAL. Spinal cord stimulation alleviates motor deficits in a primate model of Parkinson disease. Neuron. 2014 Nov 19;84(4):716-722. doi: 10.1016/j.neuron.2014.08.061. Epub 2014 Oct 30.</citation>
    <PMID>25447740</PMID>
  </reference>
  <reference>
    <citation>Jenkinson N, Nandi D, Muthusamy K, Ray NJ, Gregory R, Stein JF, Aziz TZ. Anatomy, physiology, and pathophysiology of the pedunculopontine nucleus. Mov Disord. 2009 Feb 15;24(3):319-28. doi: 10.1002/mds.22189.</citation>
    <PMID>19097193</PMID>
  </reference>
  <reference>
    <citation>Nagatsua T, Sawadab M. L-dopa therapy for Parkinson's disease: past, present, and future. Parkinsonism Relat Disord. 2009 Jan;15 Suppl 1:S3-8. doi: 10.1016/S1353-8020(09)70004-5. Review.</citation>
    <PMID>19131039</PMID>
  </reference>
  <reference>
    <citation>Liu HG, Zhang K, Yang AC, Zhang JG. Deep brain stimulation of the subthalamic and pedunculopontine nucleus in a patient with Parkinson's disease. J Korean Neurosurg Soc. 2015 Apr;57(4):303-6. doi: 10.3340/jkns.2015.57.4.303. Epub 2015 Apr 24.</citation>
    <PMID>25932301</PMID>
  </reference>
  <reference>
    <citation>Stefani A, Lozano AM, Peppe A, Stanzione P, Galati S, Tropepi D, Pierantozzi M, Brusa L, Scarnati E, Mazzone P. Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease. Brain. 2007 Jun;130(Pt 6):1596-607. Epub 2007 Jan 24.</citation>
    <PMID>17251240</PMID>
  </reference>
  <reference>
    <citation>Ferraye MU, Debû B, Fraix V, Goetz L, Ardouin C, Yelnik J, Henry-Lagrange C, Seigneuret E, Piallat B, Krack P, Le Bas JF, Benabid AL, Chabardès S, Pollak P. Effects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson's disease. Brain. 2010 Jan;133(Pt 1):205-14. doi: 10.1093/brain/awp229. Epub 2009 Sep 22.</citation>
    <PMID>19773356</PMID>
  </reference>
  <reference>
    <citation>Giladi N, Horak FB, Hausdorff JM. Classification of gait disturbances: distinguishing between continuous and episodic changes. Mov Disord. 2013 Sep 15;28(11):1469-73. doi: 10.1002/mds.25672. Review.</citation>
    <PMID>24132835</PMID>
  </reference>
  <reference>
    <citation>Fuentes R, Petersson P, Siesser WB, Caron MG, Nicolelis MA. Spinal cord stimulation restores locomotion in animal models of Parkinson's disease. Science. 2009 Mar 20;323(5921):1578-82. doi: 10.1126/science.1164901.</citation>
    <PMID>19299613</PMID>
  </reference>
  <reference>
    <citation>Fénelon G, Goujon C, Gurruchaga JM, Cesaro P, Jarraya B, Palfi S, Lefaucheur JP. Spinal cord stimulation for chronic pain improved motor function in a patient with Parkinson's disease. Parkinsonism Relat Disord. 2012 Feb;18(2):213-4. doi: 10.1016/j.parkreldis.2011.07.015. Epub 2011 Aug 23.</citation>
    <PMID>21865071</PMID>
  </reference>
  <reference>
    <citation>Hassan S, Amer S, Alwaki A, Elborno A. A patient with Parkinson's disease benefits from spinal cord stimulation. J Clin Neurosci. 2013 Aug;20(8):1155-6. doi: 10.1016/j.jocn.2012.08.018. Epub 2013 Feb 26.</citation>
    <PMID>23453160</PMID>
  </reference>
  <reference>
    <citation>Agari T, Date I. Spinal cord stimulation for the treatment of abnormal posture and gait disorder in patients with Parkinson's disease. Neurol Med Chir (Tokyo). 2012;52(7):470-4.</citation>
    <PMID>22850494</PMID>
  </reference>
  <reference>
    <citation>Landi A, Trezza A, Pirillo D, Vimercati A, Antonini A, Sganzerla EP. Spinal cord stimulation for the treatment of sensory symptoms in advanced Parkinson's disease. Neuromodulation. 2013 May-Jun;16(3):276-9. doi: 10.1111/ner.12005. Epub 2012 Dec 10.</citation>
    <PMID>23227965</PMID>
  </reference>
  <reference>
    <citation>Yadav AP, Fuentes R, Zhang H, Vinholo T, Wang CH, Freire MA, Nicolelis MA. Chronic spinal cord electrical stimulation protects against 6-hydroxydopamine lesions. Sci Rep. 2014 Jan 23;4:3839. doi: 10.1038/srep03839.</citation>
    <PMID>24452435</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2017</study_first_submitted>
  <study_first_submitted_qc>March 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2017</study_first_posted>
  <last_update_submitted>March 13, 2017</last_update_submitted>
  <last_update_submitted_qc>March 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>spinal cord stimulation</keyword>
  <keyword>gait analysis</keyword>
  <keyword>whole-body kinematics</keyword>
  <keyword>Parkinson's disease</keyword>
  <keyword>Neuromodulation</keyword>
  <keyword>Feature extraction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

